Blog Posts

Divisions Among 340B Provider, Manufacturer, and Oncology Stakeholders on Stark Display During Webinar

Champions for 340B health centers and hospitals on one side and drug manufacturers and oncologists in private practice on the other faced off yesterday during a webinar on 340B hosted by STAT.

Champions for safety-net health care providers on one side and drug manufacturers and oncologists in private practice on the other faced off yesterday during a health care news service’s webinar on the 340B program.

Please Login

Read More »

340B Hospitals and Independent Oncologists Issue Dueling Reports on Drug Discount Program

340B hospitals and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.

Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.

Please Login or Become a Paid Subscriber to View this

Read More »

Judge Schedules Joint Hearing in Novartis and United Therapeutics’ 340B Contract Pharmacy Cases

U.S. District Judge Dabney Friedrich scheduled an Oct. 12 joint hearing on pending motions in drug manufacturers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

A federal district judge in Washington, D.C., yesterday scheduled an Oct. 12 joint hearing on pending motions in drug manufacturers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

Please Login or Become a Paid Subscriber to

Read More »

Sanofi Reaches Out to 340B Entities that Complained to HRSA About its Contract Pharmacy Restrictions

Sanofi has sent letters to 340B covered entities that have complained to HRSA about the drug manufacturer's denials of 340B pricing on drugs shipped to contract pharmacies.

Drug manufacturer Sanofi has sent letters to 340B covered entities that have complained to federal authorities about its denials of 340B pricing on drugs shipped to contract pharmacies, covered entity representatives say.

Please Login or Become

Read More »

Biden Administration Moves a Step Closer to Trashing Trump’s 340B Health Center Insulin/EpiPen Rule

Former President Trump signed an executive order in July 2020 directing HHS to limit what 340B health centers can charge patients for insulin and EpiPen-type devices.

The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.

Please Login or Become a

Read More »

Keys to Ensuring Adherence in HIV Treatment and Care

SPONSORED CONTENT

An HIV diagnosis does not have the same meaning today as when the virus first emerged in the 1980s. People living with HIV can now expect to live a long, full life, as long as they adhere to a prescribed antiretroviral treatment regimen. AIDS Healthcare Foundation (AHF), the largest provider of HIV/AIDS medical care globally, plays a key

Read More »

Arkansas Insurance Dept. to Rule Next Month on PhRMA’s Petition to Block Novel 340B Contract Pharmacy Law

An Arkansas Insurance Department hearing officer said last week she would decide by Oct. 13 whether to stay enforcement of a state law requiring drug manufacturers to honor 340B contract pharmacy arrangements.

An Arkansas Insurance Department hearing officer said last week she would decide by Oct. 13 whether to stay enforcement of a state law requiring drug manufacturers to honor 340B contract pharmacy arrangements pending resolution of a bevy of federal lawsuits

Read More »

U.S. Supreme Court Gets Several Briefs Urging Rejection of CMS’s Drug Payment Cuts for 340B Hospitals

Nine friend-of-the-court briefs have been filed urging the U.S. Supreme Court to strike down the CMS rule that imposed a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.

Nine friend-of-the-court briefs have been filed in the nation’s highest court urging rejection of an appeals court’s decision last year that upheld a huge cut in 340B hospitals’ Medicare reimbursement for physician administered drugs.

Please Login

Read More »

Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug

Napo Pharmaceuticals has told covered entities how they can continue to buy Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs, at its 340B price.

Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.

Please Login or Become a Paid

Read More »

The Power of Partnership: Work with an Administrator that Understands Independent Pharmacies

SPONSORED CONTENT

It is my pleasure to introduce our company to 340B Report’s readers. RxPreferred Benefits is a fully transparent 340B Administrator and Pharmacy Benefit Manager (PBM) founded, and solely owned, by independent pharmacy representatives. Privately held and headquartered in Nashville, TN, RxPreferred operates nationally, partnering with a wide range of clients including: 340B covered entities, self-funded employers, hospitals, health systems, hospices, pharmacies, brokers, and third-party administrators.

Zero Conflicts-of-Interest

Read More »
Generic selectors
Exact matches only
Search in title
Search in content